Jian Ding (Shanghai)

Shanghai Institute of Materia Medica .
Chinese Academy of Sciences.
555 Zu Chong Zhi Road.
Shanghai 201203, P.R. China.

Jian Ding, M.D. received his B.S. from Jiangxi Medical University (Jiangxi, China) and his M.D. from Kyushu University (Fukuoka, Japan). He was a postdoctoral fellow at the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences. Since 1994, he has been the principal investigator of the Division of Antitumor Pharmacology at the Shanghai Institute of Materia Medica. He currently serves as Editor-in-chief of Acta Pharmacologica Sinica and is on the Editorial Board of Eur J Pharmacol, J Ethnopharm and Cancer Biology & Therapy.

Areas of Focus
Anti-Tumor Pharmacology
Tumor Biology

Research Interests:

Research in the Ding lab is directed towards the following two fields: (1) Screening, research and development of new anticancer drugs including topoisomerase inhibitors, microtubule inhibitors, tumor angiogenesis inhibitors, tyrosine kinase inhibitors, heparanase inhibitors and PI3K/mTOR inhibitors; (2). Cellular and molecular mechanisms of actions of anticancer drugs, particularly DNA damage and DNA repair, signaling transduction in tumor cells, tumor multidrug resistance and tumor metastasis.

Selected papers:

1. Wang X, Zhang M, Ping F, Liu H, Sun J, Wang Y, Shen A, Ding J*, Geng M. Identification and Therapeutic Intervention of Co-activated ALK, FGFR2 and EphA5 Kinases in Hepatocellular Carcinoma. Hepatology. 2018 Jan 21. doi: 10.1002/hep.29792. [Epub ahead of print]

2. Shi JJ, Chen SM, Guo CL, Li YX, Ding J*, Meng LH. The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8. Acta Pharmacol Sin. 2018 Jan 18. doi: 10.1038/aps.2017.181. [Epub ahead of print]

3. Chen X, Huan X, Liu Q, Wang Y, He Q, Tan C, Chen Y, Ding J*, Xu Y, Miao Z, Yang C. Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors. Eur J Med Chem. 2018 Jan 8;145:389-403. doi: 10.1016/j.ejmech.2018.01.018. [Epub ahead of print]

4. Ai J, Chen Y, Peng X, Ji Y, Xi Y, Shen Y, Yang X, Su Y, Sun YM, Gao Y, Ma Y, Xiong B, Shen J, Ding J*, Geng M. Preclinical evaluation of SCC244 (Glumetinib), a novel, potent and highly selective inhibitor of c-Met in MET-dependent cancer models. Mol Cancer Ther. 2017 Dec 13. doi: 10.1158/1535-7163.MCT-17-0368. [Epub ahead of print]

5. Wang YF, Zhang J, Su Y, Shen YY, Jiang DX, Hou YY, Geng MY, Ding J*, Chen Y. G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. Nat Commun. 2017 Aug 17;8(1):274. doi: 10.1038/s41467-017-00350-9.

6. Li X, Tang S, Wang QQ, Leung EL, Jin H, Huang Y, Liu J, Geng M, Huang M, Yuan S, Yao XJ, Ding J*. Identification of Epigallocatechin-3- Gallate as an Inhibitor of Phosphoglycerate Mutase 1. Front Pharmacol. 2017 May 30;8:325. doi: 10.3389/fphar.2017.00325.

7. Lian Q, Xu J, Yan S, Huang M, Ding H, Sun X, Bi A, Ding J*, Sun B, Geng M. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. Cell Res. 2017 Jun;27(6):784-800. doi: 10.1038/cr.2017.54. Epub 2017 Apr 14.

8. He JX, Wang M, Huan XJ, Chen CH, Song SS, Wang YQ, Liao XM, Tan C, He Q, Tong LJ, Wang YT, Li XH, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Gao ZW, Chen XY, Xiong B, Lu XL, Ding J*, Yang CH, Miao ZH. Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution. Oncotarget. 2017 Jan 17;8(3):4156-4168. doi: 10.18632/oncotarget.13749.

9. Zeng H, Qu J, Jin N, Xu J, Lin C, Chen Y, Yang X, He X, Tang S, Lan X, Yang X, Chen Z, Huang M, Ding J*, Geng M. Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer. Cancer Cell. 2016 Sep 12;30(3):459-473. doi: 10.1016/j.ccell.2016.08.001.

10. Ni G, Zhang H, Fan YY, Liu HC, Ding J*, Yue JM. Mannolides A-C with an Intact Diterpenoid Skeleton Providing Insights on the Biosynthesis of Antitumor Cephalotaxus Troponoids. Org Lett. 2016 Apr 15;18(8):1880-3. doi: 10.1021/acs.orglett.6b00653. Epub 2016 Apr 4.

11. Zhou C, Dai X, Chen Y, Shen Y, Lei S, Xiao T, Bartfai T, Ding J*, Wang MW. G protein-coupled receptor GPR160 is associated with apoptosis and cell cycle arrest of prostate cancer cells. Oncotarget. 2016 Mar 15;7(11):12823-39. doi: 10.18632/oncotarget.7313.

12. Shen A, Wang L, Huang M, Sun J, Chen Y, Shen YY, Yang X, Wang X, Ding J*, Geng M. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. Cancer Res. 2015 Nov 1;75(21):4548-59. doi: 10.1158/0008-5472.CAN-14-2743. Epub 2015 Oct 19.

13. Wang X, Ding J*, Meng LH. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies. Acta Pharmacol Sin. 2015 Oct;36(10):1170-6. doi: 10.1038/aps.2015.71. Epub 2015 Sep 14. Review.

14. Yi JM, Zhang XF, Huan XJ, Song SS, Wang W, Tian QT, Sun YM, Chen Y, Ding J*, Wang YQ, Yang CH, Miao ZH. Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition. Oncotarget. 2015 Apr 20;6(11):8960-73.

15. He PX, Che YS, He QJ, Chen Y, Ding J*. G226, a novel epipolythiodioxopiperazine derivative, induces autophagy and caspase-dependent apoptosis in human breast cancer cells in vitro. Acta Pharmacol Sin. 2014 Aug;35(8):1055-64. doi: 10.1038/aps.2014.47.

16. Li JX, Feng JM, Wang Y, Li XH, Chen XX, Su Y, Shen YY, Chen Y, Xiong B, Yang CH, Ding J*, Miao ZH. The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis. 2014 Jun 5;5:e1278. doi: 10.1038/cddis.2014.241.

17. Lin LG, Xie H, Wang YT, Ding J*, Ye Y. Chemical constituents from the heartwood of Haematoxylon campechianum as protein tyrosine kinase inhibitors. Chem Biodivers. 2014 May;11(5):776-83. doi: 10.1002/cbdv.201300183.

18. Zhang HT, Wang L, Ai J, Chen Y, He CX, Ji YC, Huang M, Yang JY, Zhang A, Ding J*, Geng MY. SOMG-833, a novel selective c-MET inhibitor, blocks c-MET-dependent neoplastic effects and exerts antitumor activity. J Pharmacol Exp Ther. 2014 Jul;350(1):36-45. doi: 10.1124/jpet.114.214817. Epub 2014 Apr 16.

19. Liu JL, Gao GR, Zhang X, Cao SF, Guo CL, Wang X, Tong LJ, Ding J*, Duan WH, Meng LH. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R). J Pharmacol Exp Ther. 2014 Mar;348(3):432-41. doi: 10.1124/jpet.113.210724. Epub 2013 Dec 20.

20. Huang M, Shen A, Ding J*, Geng M. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci. 2014 Jan;35(1):41-50. doi: 10.1016/j.tips.2013.11.004. Epub 2013 Dec 19. Review.

21. Huang X, Pan Q, Sun D, Chen W, Shen A, Huang M, Ding J*, Geng M. O-GlcNAcylation of cofilin promotes breast cancer cell invasion. J Biol Chem. 2013 Dec 20;288(51):36418-25. doi: 10.1074/jbc.M113.495713. Epub 2013 Nov 8.

22. Xu L, Feng JM, Li JX, Zhu JM, Song SS, Tong LJ, Chen Y, Yang XY, Shen YY, Lian FL, Li YP, Lin DH, Ding J*, Miao ZH. Tanshinone-1 induces tumor cell killing, enhanced by inhibition of secondary activation of signaling networks. Cell Death Dis. 2013 Nov 7;4:e905. doi: 10.1038/cddis.2013.443.

23. Feng JM, Miao ZH, Jiang Y, Chen Y, Li JX, Tong LJ, Zhang J, Huang YR, Ding J*. Characterization of the conversion between CD133+ and CD133- cells in colon cancer SW620 cell line. Cancer Biol Ther. 2012 Dec;13(14):1396-406. doi: 10.4161/cbt.22000. Epub 2012 Sep 6.

24. Wang S, Huang X, Sun D, Xin X, Pan Q, Peng S, Liang Z, Luo C, Yang Y, Jiang H, Huang M, Chai W, Ding J*, Geng M. Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates Akt signaling. PLoS One. 2012;7(5):e37427. doi: 10.1371/journal.pone.0037427. Epub 2012 May 22.

25. Chen SM, Liu JL, Wang X, Liang C, Ding J*, Meng LH. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR. Biochem Pharmacol. 2012 May 1;83(9):1183-94. doi: 10.1016/j.bcp.2012.01.019. Epub 2012 Jan 26.

26. Ai J, Tang Q, Wu Y, Xu Y, Feng T, Zhou R, Chen Y, Gao X, Zhu Q, Yue X, Pan Q, Xu S, Li J, Huang M, Daugherty-Holtrop J, He Y, Xu HE, Fan J, Ding J*, Geng M. The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma. J Natl Cancer Inst. 2011 Nov 16;103(22):1696-712. doi: 10.1093/jnci/djr360. Epub 2011 Oct 24.

27. Xie H, Lin L, Tong L, Jiang Y, Zheng M, Chen Z, Jiang X, Zhang X, Ren X, Qu W, Yang Y, Wan H, Chen Y, Zuo J, Jiang H, Geng M, Ding J*. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6(7):e21487. doi: 10.1371/journal.pone.0021487. Epub 2011 Jul 18.

28.Jiang Y, Miao ZH, Xu L, Yu B, Gong JX, Tong LJ, Chen Y, Zhou ZL, Liu HC, Wang Y, Guo YW, Ding J*. Drug transporter-independent liver cancer cell killing by a marine steroid methyl spongoate via apoptosis induction. J Biol Chem. 2011 Jul 29;286(30):26461-9. doi: 10.1074/jbc.M111.232728. Epub 2011 Jun 9.

29. Lu JJ, Cai YJ, Ding J*. Curcumin induces DNA damage and caffeine-insensitive cell cycle arrest in colorectal carcinoma HCT116 cells. Mol Cell Biochem. 2011 Aug;354(1-2):247-52. doi: 10.1007/s11010-011-0824-3. Epub 2011 Apr 28.

30.Ma JG, Huang H, Chen SM, Chen Y, Xin XL, Lin LP, Ding J*, Liu H, Meng LH. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo. Breast Cancer Res Treat. 2011 Nov;130(1):85-96. doi: 10.1007/s10549-010-1302-4. Epub 2010 Dec 22.

31.Zhu C, Chen Q, Xie Z, Ai J, Tong L, Ding J*, Geng M. The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc. J Mol Med (Berl). 2011 Mar;89(3):279-89. doi: 10.1007/s00109-010-0701-7. Epub 2010 Dec 1.

32.Zhou ZL, Luo ZG, Yu B, Jiang Y, Chen Y, Feng JM, Dai M, Tong LJ, Li Z, Li YC, Ding J*, Miao ZH. Increased accumulation of hypoxia-inducible factor-1α with reduced transcriptional activity mediates the antitumor effect of triptolide. Mol Cancer. 2010 Oct 11;9:268. doi: 10.1186/1476-4598-9-268.

33.Li T, Wang J, Wang X, Yang N, Chen SM, Tong LJ, Yang CH, Meng LH, Ding J*. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant. J Pharmacol Exp Ther. 2010 Sep 1;334(3):830-8. doi: 10.1124/jpet.110.167940. Epub 2010 Jun 3.

34.Chen G, Yang N, Wang X, Zheng SY, Chen Y, Tong LJ, Li YX, Meng LH, Ding J*. Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer. J Mol Med (Berl). 2010 Sep;88(9):941-52. doi: 10.1007/s00109-010-0635-0. Epub 2010 May 28.

35.Lu JJ, Meng LH, Shankavaram UT, Zhu CH, Tong LJ, Chen G, Lin LP, Weinstein JN, Ding J*. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol. 2010 Jul 1;80(1):22-30. doi: 10.1016/j.bcp.2010.02.016. Epub 2010 Mar 3.

36.Chen SM, Meng LH, Ding J*. New microtubule-inhibiting anticancer agents. Expert Opin Investig Drugs. 2010 Mar;19(3):329-43. doi: 10.1517/13543780903571631. Review.

37.Zhu H, Miao ZH, Huang M, Feng JM, Zhang ZX, Lu JJ, Cai YJ, Tong LJ, Xu YF, Qian XH, Ding J*. Naphthalimides induce G(2) arrest through the ATM-activated Chk2-executed pathway in HCT116 cells. Neoplasia. 2009 Nov;11(11):1226-34.

38.Li M, Miao ZH, Chen Z, Chen Q, Gui M, Lin LP, Sun P, Yi YH, Ding J*. Echinoside A, a new marine-derived anticancer saponin, targets topoisomerase2alpha by unique interference with its DNA binding and catalytic cycle. Ann Oncol. 2010 Mar;21(3):597-607. doi: 10.1093/annonc/mdp335. Epub 2009 Sep 22.

39.Yu B, Miao ZH, Jiang Y, Li MH, Yang N, Li T, Ding J*. c-Jun protects hypoxia-inducible factor-1alpha from degradation via its oxygen-dependent degradation domain in a nontranscriptional manner. Cancer Res. 2009 Oct 1;69(19):7704-12. doi: 10.1158/0008-5472.CAN-09-0808. Epub 2009 Sep 8.

40.Ren X, Dai M, Lin LP, Li PK, Ding J*. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent. Br J Pharmacol. 2009 Apr;156(8):1228-38. doi: 10.1111/j.1476-5381.2009.00112.x. Epub 2009 Mar 19.

41.Ma J, Xin X, Meng L, Tong L, Lin L, Geng M, Ding J*. The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo. PLoS One. 2008;3(11):e3774. doi: 10.1371/journal.pone.0003774. Epub 2008 Nov 20.

42.Feng JM, Zhu H, Zhang XW, Ding J*, Miao ZH. Proteasome-dependent degradation of Chk1 kinase induced by the topoisomerase II inhibitor R16 contributes to its anticancer activity. Cancer Biol Ther. 2008 Nov;7(11):1726-31. Epub 2008 Nov 4.

43.Lin LG, Xie H, Li HL, Tong LJ, Tang CP, Ke CQ, Liu QF, Lin LP, Geng MY, Jiang H, Zhao WM, Ding J*, Ye Y. Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening. J Med Chem. 2008 Aug 14;51(15):4419-29. doi: 10.1021/jm701501x. Epub 2008 Jul 9.

44.Wu D, Hu T, Zhang L, Chen J, Du J, Ding J*, Jiang H, Shen X. Residues Asp164 and Glu165 at the substrate entryway function potently in substrate orientation of alanine racemase from E. coli: Enzymatic characterization with crystal structure analysis. Protein Sci. 2008 Jun;17(6):1066-76. doi: 10.1110/ps.083495908. Epub 2008 Apr 23.

45.Shen Y, Zhang YW, Zhang ZX, Miao ZH, Ding J*. hTERT-targeted RNA interference inhibits tumorigenicity and motility of HCT116 cells. Cancer Biol Ther. 2008 Feb;7(2):228-36. Epub 2007 Nov 3.

46.Meng LH, Ding J*. Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation. Acta Pharmacol Sin. 2007 Sep;28(9):1460-5. Review.

47.Tian F, Zhu CH, Zhang XW, Xie X, Xin XL, Yi YH, Lin LP, Geng MY, Ding J*. Philinopside E, a new sulfated saponin from sea cucumber, blocks the interaction between kinase insert domain-containing receptor (KDR) and alphavbeta3 integrin via binding to the extracellular domain of KDR.Mol Pharmacol. 2007 Sep;72(3):545-52. Epub 2007 Jun 12.

48.Huang M, Gao H, Chen Y, Zhu H, Cai Y, Zhang X, Miao Z, Jiang H, Zhang J, Shen H, Lin L, Lu W, Ding J*. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo. Clin Cancer Res. 2007 Feb 15;13(4):1298-307. Epub 2007 Feb 7.

49.Zhao H, Liu H, Chen Y, Xin X, Li J, Hou Y, Zhang Z, Zhang X, Xie C, Geng M, Ding J*. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis. Cancer Res. 2006 Sep 1;66(17):8779-87.

50.Hu CX, Zuo ZL, Xiong B, Ma JG, Geng MY, Lin LP, Jiang HL, Ding J*. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Mol Pharmacol. 2006 Nov;70(5):1593-601. Epub 2006 Aug 16.

51.Gao Y, Lin LP, Zhu CH, Chen Y, Hou YT, Ding J*. Growth arrest induced by C75, A fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma. Cancer Biol Ther. 2006 Aug;5(8):978-85. Epub 2006 Aug 3.

52.Zhang C, Yang F, Zhang XW, Wang SC, Li MH, Lin LP, Ding J*. Grateloupia longifolia polysaccharide inhibits angiogenesis by downregulating tissue factor expression in HMEC-1 endothelial cells. Br J Pharmacol. 2006 Jul;148(6):741-51. Epub 2006 May 22.

53.Ding J*, Miao ZH, Meng LH, Geng MY. Emerging cancer therapeutic opportunities target DNA-repair systems. Trends Pharmacol Sci. 2006 Jun;27(6):338-44. Epub 2006 May 11. Review.

54.Lu HR, Zhu H, Huang M, Chen Y, Cai YJ, Miao ZH, Zhang JS, Ding J*. Reactive oxygen species elicit apoptosis by concurrently disrupting topoisomerase II and DNA-dependent protein kinase. Mol Pharmacol. 2005 Oct;68(4):983-94. Epub 2005 Jul 15.

55.Chen Y, Miao ZH, Zhao WM, Ding J*. The p53 pathway is synergized by p38 MAPK signaling to mediate 11,11'-dideoxyverticillin-induced G2/M arrest. FEBS Lett. 2005 Jul 4;579(17):3683-90.

56.Lu DY, Huang M, Xu CH, Yang WY, Hu CX, Lin LP, Tong LJ, Li MH, Lu W, Zhang XW, Ding J*. Anti-proliferative effects, cell cycle G2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines. BMC Pharmacol. 2005 Jun 20;5:11.

57.Lang JY, Chen H, Zhou J, Zhang YX, Zhang XW, Li MH, Lin LP, Zhang JS, Waalkes MP, Ding J*. Antimetastatic effect of salvicine on human breast cancer MDA-MB-435 orthotopic xenograft is closely related to Rho-dependent pathway. Clin Cancer Res. 2005 May 1;11(9):3455-64.